Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase NA 2Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Pancreatic Neoplasms 7Breast Neoplasms 7Colorectal Neoplasms 6Stomach Neoplasms 5Neoplasms 5Sarcoma 3Precision Cell Immunotherapy 3Ovarian Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Glioblastoma 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Mesothelioma 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Ovarian Epithelial 2Virus Diseases 1

Interventions

Rituximab 47Cyclophosphamide 45fludarabine 22Filgrastim 21Lenalidomide 18fludarabine phosphate 17Prednisone 16Radiotherapy 15Peripheral Blood Stem Cell Transplantation 15Etoposide 15Vincristine 14Doxorubicin 14Melphalan 13Busulfan 13pembrolizumab 11Tacrolimus 11Methotrexate 10Gemcitabine 10ibrutinib 9Bendamustine Hydrochloride 9Alemtuzumab 9obinutuzumab 8Bortezomib 8Vorinostat 7Mycophenolic Acid 7Granulocyte Colony-Stimulating Factor 7Carboplatin 7Azacitidine 7venetoclax 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma × Drug Therapy × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT04764513 2022-03-28

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

Chinese PLA General Hospital

Phase 1/2 Unknown
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡